Paul Norwood
Endocrinology, Diabetes & Metabolism · Fresno, CANPI 1871503649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,523 of the $19,970 with a category attached, or 72.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2019 at $7,871 and has fallen 80.5% since, to $1,537 in 2025.
Across 694 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- Sanofi-aventis U.S. LLC$2K
- Novo Nordisk$2K
- Eli Lilly$1K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- plus $7K from 54 others
Across 3,554 payments — averaging $1757.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.1M
- Novo Nordisk AS$2.2M
- Sanofi US Services Inc.$174K
- Biogen$146K
- Medtronic$105K
- Pfizer$97K
- plus $372K from 8 others
What the payments were for
- Speaking & faculty fees$3,18516%
- Travel & lodging$2,18711%
- Food & beverage$14,52373%
- Education$150%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$344
- TZIELD$264
- Omnia$186
- INTELLIS ADAPTIVESTIM$131
- PROCLAIM$127
- TEPEZZA$125
- Vascepa$125
- FARXIGA$125
- Inpefa$125
- ETERNA$120
- Senza$114
- SOLIQUA 100/33$112
- FREESTYLE LIBRE 3$112
- FreeStyle Libre 2$111
- CRENESSITY$103
- Evoke$101
How this compares
$19,970 in reported general payments places this provider in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 413 | $708,940 |
| JardianceEmpagliflozin | 256 | $333,022 |
| TrulicityDulaglutide | 127 | $222,048 |
| MounjaroTirzepatide | 145 | $175,654 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 49 | $141,310 |
| Tresiba Flextouch U-200Insulin Degludec | 88 | $127,510 |
| FarxigaDapagliflozin Propanediol | 85 | $110,117 |
| Tresiba Flextouch U-100Insulin Degludec | 161 | $103,949 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 58 | $77,079 |
| Humalog Kwikpen U-100Insulin Lispro | 164 | $72,547 |
| EliquisApixaban | 43 | $60,255 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 104 | $57,622 |
| Novolog FlexpenInsulin Aspart | 163 | $55,357 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $51,112 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $46,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,709 | $757,894464 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,461 | $408,653316 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $336 | $355,379271 claims |
| AstraZenecaFarxiga | $1,342 | $110,11785 claims |
| PfizerEliquis | $102 | $60,25543 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,972 | $44,87340 claims |
| BayerKerendia | $169 | $27,19828 claims |
| Johnson & JohnsonInvokana | $66 | $18,04311 claims |
| GSKBreo Ellipta | $17 | $13,12523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Fresno
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.